This is a StreetInsider.com Premium Only Page

Takeda (TAK) – StreetInsider.com Reports

Apr 18, 2024 07:08 PM Takeda (TAK) U.S. FDA Approves Subcutaneous Administration of ENTYVIO

Mar 20, 2024 09:02 AM Scilex Holding (SCLX) Enters Settlement Agreement with Takeda Pharmaceuticals (TAK)

Mar 19, 2024 12:20 PM Takeda (TAK) Announces U.S. FDA Approval of sNDA for ICLUSIG in Adult Patients with Newly Diagnosed Ph+ ALL

Mar 19, 2024 06:31 AM Centogene N.V. (CNTG) Extends Strategic Partnership With Takeda (TAK)

Mar 13, 2024 08:00 AM Takeda (TAK) Announces Positive Topline Results from Phase 2 Study of Mezagitamab

Mar 8, 2024 11:26 AM Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY4,300 at JPMorgan

Feb 12, 2024 08:03 AM Takeda (TAK) Announces FDA Approval of EOHILIA

Feb 9, 2024 02:30 AM Takeda (TAK) to Rapidly Initiate the First Global Phase 3 Trials of TAK-861

Feb 1, 2024 05:44 AM Takeda Pharmaceutical (TAK) Announces CFO Transition

Jan 31, 2024 04:09 PM Takeda (TAK) and Protagonist Therapeutics (PTGX) Enter Global License and Collaboration Agreement for Rusfertide

Jan 29, 2024 11:10 AM Takeda’s (TAK) GAMMAGARD LIQUID Approved by U.S. FDA for Adults with CIDP

Jan 29, 2024 05:55 AM Takeda's (TAK) HYQVIA Approved in EU as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Jan 16, 2024 08:17 AM Halozyme (HALO) Announces Takeda (TAK) Receives FDA Approval for HYQVIA Co-formulated with ENHANZE as Maintenance Therapy in Adults with CIDP

Jan 16, 2024 08:04 AM Takeda Pharmaceutical (TAK) Announces FDA Approval of HYQVIA

Dec 29, 2023 09:19 AM Pfizer (PFE), Sanofi (SNY) and Takeda (TAK) to raise prices on over 500 drugs in the US in January - Reuters

Dec 21, 2023 04:00 PM Takeda Pharmaceutical (TAK) Announces China NMPA Approval of LIVTENCITY

Dec 21, 2023 07:35 AM Takeda Pharmaceutical (TAK) and JCR Pharmaceuticals Announce Discontinuation of Gene Therapy Collaboration

Dec 15, 2023 08:16 AM Takeda Pharmaceutical (TAK) Receives Positive CHMP Opinion for HYQVIA

Nov 9, 2023 03:50 PM Takeda Pharmaceutical (TAK) Announces FDA Approval of ADZYNMA

Nov 8, 2023 05:57 PM Takeda (TAK) Announces FDA Approval of FRUZAQLA

Nov 7, 2023 10:00 AM Takeda (TAK) Announces Late-Breaking Data from Phase 2b Study of TAK-279

Nov 6, 2023 02:35 AM Takeda Pharmaceutical (4502:JP) (TAK) PT Lowered to JPY4,300 at Citi

Oct 23, 2023 11:04 AM UBS Starts Takeda Pharmaceutical (4502:JP) (TAK) at Neutral

Oct 18, 2023 04:30 PM Takeda Pharmaceutical (TAK) Announces EU Approval of ADCETRIS for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

Oct 17, 2023 07:31 PM Takeda Pharmaceutical (TAK) Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire

Oct 17, 2023 07:31 PM Takeda Pharmaceutical (TAK) Reports Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel

Oct 3, 2023 06:29 AM Takeda Pharmaceutical (4502:JP) (TAK) PT Lowered to JPY5,200 at Jefferies

Oct 2, 2023 04:35 PM Takeda (TAK) Provides Update on EXKIVITY

Sep 27, 2023 04:26 PM Takeda Pharmaceutical (TAK) Announces FDA Approval of Subcutaneous Administration of ENTYVI for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Sep 25, 2023 08:45 AM Takeda Pharmaceutical (TAK) Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan

Sep 22, 2023 12:46 AM Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY5,300 at Jefferies

Sep 20, 2023 08:02 AM Takeda Pharmaceutical (TAK) Announces FDA Acceptance of NDA Resubmission of TAK-721

Sep 13, 2023 08:01 AM Takeda Pharmaceutical (TAK) Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO

Sep 11, 2023 06:46 AM Takeda (TAK) Reports Positive Topline Results from Phase 2b Study of TAK-279

Aug 28, 2023 06:30 AM Immunogen (IMGN) Collaborates with Takeda (TAK) to Develop and Commercialize ELAHERE in Japan

Aug 9, 2023 05:36 AM Takeda Pharmaceutical (4502:JP) (TAK) PT Lowered to JPY4,600 at Citi

Jul 29, 2023 07:31 AM Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY5,800 at Nomura/Instinet

Jul 26, 2023 05:12 PM Takeda Pharmaceutical (TAK) Reports Publication of Data from Phase 2 Study of TAK-994

Jul 21, 2023 11:51 AM Takeda Pharmaceutical (4502:JP) (TAK) PT Lowered to JPY4,800 at Macquarie

Jul 6, 2023 11:13 AM Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY4,100 at JPMorgan

Jul 6, 2023 03:43 AM Takeda Pharmaceutical (TAK) PT Lowered to $14.20 at JPMorgan

Jun 20, 2023 08:46 AM Takeda Pharmaceutical (TAK) Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Trial of HYQVIA

Jun 16, 2023 06:00 AM Takeda Pharmaceutical (TAK) and HUTCHMED (HCM) Announce Publication of Phase 3 FRESCO-2 Results

Jun 13, 2023 02:36 AM Takeda Pharmaceutical (TAK) PT Lowered to $18.60 at BofA Securities

May 31, 2023 01:29 PM Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY5,100 at Jefferies

May 26, 2023 07:31 AM Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY4,200 at Morgan Stanley

May 25, 2023 04:31 PM Takeda Pharmaceutical (TAK) and HUTCHMED (HCM) Announce New Drug Application (NDA) for Fruquintinib

May 22, 2023 04:32 AM Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY4,700 at Citi

May 16, 2023 08:11 AM Takeda Pharmaceutical (TAK) PT Lowered to $20 at TD Cowen

May 15, 2023 10:58 AM Takeda Pharmaceutical (4502:JP) (TAK) PT Lowered to JPY5,600 at Nomura/Instinet